^
Association details:
| Biomarker: | YES1 amplification |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) + Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
Published date:
11/26/2021
Excerpt:
YES1 was amplified in BT-474-R and further amplified in BT-474-R/TDR (Figure 3A)....In both assays, the combination of T-DM1 with dasatinib was found to be effective in BT-474-R and BT-474-R/TDR....In BT-474-R/TDR, there was no apoptosis with dasatinib alone, but apoptosis was induced by the combination therapy.
DOI:
10.3390/ijms222312809